Celldex Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Celldex Therapeutics Inc Unternehmen

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Celldex Therapeutics Inc Informationen



BörsenkürzelCLDX

Name des UnternehmensCelldex Therapeutics Inc

IPO-datumMay 15, 1986

CEOMr. Anthony S. Marucci

Anzahl der mitarbeiter186

WertpapierartOrdinary Share

GeschäftsjahresendeMay 15

Addresse53 Frontage Road

StadtHAMPTON

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl08827

Telefon19084547120

Websitehttps://celldex.com/

BörsenkürzelCLDX

IPO-datumMay 15, 1986

CEOMr. Anthony S. Marucci

Führungskräfte von Celldex Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Mr. Herbert J. (Herb) Conrad

Independent Director

2.56K

--

Mr. James J. (Jim) Marino

Independent Director

2.20K

--

Mr. Keith L. Brownlie, CPA

Independent Director

666.00

--

Ms. Teri L. Lawver

Senior Vice President, Chief Commercial Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sat, Aug 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

Andere

60.89%

Aktionäre

Anteil

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

Andere

60.89%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

42.58%

Hedge Fund

32.92%

Investment Advisor/Hedge Fund

31.28%

Venture Capital

3.61%

Research Firm

2.78%

Pension Fund

0.39%

Bank and Trust

0.36%

Individual Investor

0.27%

Insurance Company

0.04%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

420

73.66M

110.92%

-14.44M

2025Q2

422

75.86M

114.26%

-13.90M

2025Q1

437

75.31M

113.46%

-13.68M

2024Q4

437

75.05M

113.05%

-8.14M

2024Q3

429

73.28M

110.59%

-7.16M

2024Q2

432

71.48M

107.86%

-10.62M

2024Q1

419

71.32M

108.50%

+952.72K

2023Q4

406

62.72M

112.33%

-412.93K

2023Q3

403

52.10M

110.18%

-8.63M

2023Q2

410

51.84M

109.57%

-7.47M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Wellington Management Company, LLP

5.23M

7.88%

-3.12M

-37.37%

Jun 30, 2025

Kynam Capital Management LP

6.10M

9.19%

-399.27K

-6.14%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.59M

6.91%

-38.52K

-0.83%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.95M

5.95%

+62.97K

+1.62%

Jun 30, 2025

The Vanguard Group, Inc.

3.94M

5.94%

+56.45K

+1.45%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.75M

5.65%

+398.14K

+11.88%

Jun 30, 2025

Commodore Capital LP

3.45M

5.2%

+100.00K

+2.99%

Jun 30, 2025

Bellevue Asset Management AG

3.31M

4.98%

+235.95K

+7.68%

Jun 30, 2025

Point72 Asset Management, L.P.

2.80M

4.22%

+180.55K

+6.89%

Jun 30, 2025

State Street Investment Management (US)

2.41M

3.62%

-400.86K

-14.28%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Simplify Propel Opportunities ETF

3.32%

ALPS Medical Breakthroughs ETF

1.02%

Virtus LifeSci Biotech Clinical Trials ETF

0.92%

SPDR S&P Biotech ETF

0.65%

Direxion Daily S&P Biotech Bull 3X Shares

0.34%

Avantis US Small Cap Equity ETF

0.15%

First Trust Small Cap Growth AlphaDEX Fund

0.14%

Nuveen ESG Small-Cap ETF

0.14%

Fidelity Fundamental Small-Mid Cap ETF

0.13%

T Rowe Price Small-Mid Cap ETF

0.12%

Simplify Propel Opportunities ETF

Anteil3.32%

ALPS Medical Breakthroughs ETF

Anteil1.02%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil0.92%

SPDR S&P Biotech ETF

Anteil0.65%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.34%

Avantis US Small Cap Equity ETF

Anteil0.15%

First Trust Small Cap Growth AlphaDEX Fund

Anteil0.14%

Nuveen ESG Small-Cap ETF

Anteil0.14%

Fidelity Fundamental Small-Mid Cap ETF

Anteil0.13%

T Rowe Price Small-Mid Cap ETF

Anteil0.12%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten